About Stromatis Pharma
Stromatis Pharma is a Healthcare company based in Athens (United States) founded in 2016 by Haiyong Han, Daniel Von Hoff, and Michael Pierce. Drugs for cystic fibrosis treatment are developed by Stromatis Pharma. Its focus areas include Life Sciences, Pulmonology, Drugs and COPD and Asthma. Similar companies include Innoviva, Reneo Pharmaceuticals and Sionna; 2 of its 3 listed similar companies have raised funding.
Company details
Stromatis Pharma was founded in 2016 and is headquartered in Athens, United States. Focus is placed on the pharmaceutical sector, where drugs targeting cystic fibrosis are developed. The lead product involves sFRP2 antagonists, which shift stromal stellate cells from an activated to a quiescent state, aiding in fibrosis reversal. Regulation of myocardial fibrosis following infarction is also addressed by sFRP2, establishing it as a key target for anti-fibrotic interventions.
- Headquarters Athens, United States
- Founders Haiyong Han, Daniel Von Hoff, Michael Pierce
- SectorsHealthcare
- Website stromatis.com
People of Stromatis Pharma
3 people are tracked at Stromatis Pharma (3 in leadership).
| Name | Role | Group |
|---|---|---|
Haiyong Han | Co-Founder | Leadership |
Daniel Von Hoff | Co-Founder | Leadership |
Michael Pierce | Co-Founder | Leadership |
Complete people profiles for Stromatis Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Similar companies to Stromatis Pharma
Stromatis Pharma has 3 listed similar companies in our database, 2 of them funded. They include Innoviva, Reneo Pharmaceuticals and Sionna.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inva.com | 1996 | Brisbane, United States | 101 | Respiratory prescription drugs are developed and in-licensed for COPD treatment. | ||
| reneopharma.com | 2015 | San Diego, United States | $145M | 48 | Small molecule therapies for orphan diseases are being developed. | |
| sionnatx.com | 2019 | Natick, United States | $293M | Small molecule therapeutics for cystic fibrosis are developed. |
Detailed similar companies of Stromatis Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Stromatis Pharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Stromatis Pharma
Stromatis Pharma was founded in 2016.
Stromatis Pharma is headquartered in Athens, United States.
Stromatis Pharma was founded in 2016 and is headquartered in Athens, United States. Focus is placed on the pharmaceutical sector, where drugs targeting cystic fibrosis are developed. The lead product involves sFRP2 antagonists, which shift stromal stellate cells from an activated to a quiescent state, aiding in fibrosis reversal. Regulation of myocardial fibrosis following infarction is also addressed by sFRP2, establishing it as a key target for anti-fibrotic interventions.
Stromatis Pharma's top competitors include Reneo Pharmaceuticals, Sionna and Innoviva.